Samumed Annual Revenue, Number of Employees, Growth and Funding

Claim your profile

Overview

Location:
Total Funding:$438M
Industry:Biotech
Founded:N/A
Lead Investor(s):Vickers Venture Partners, Starling group
Press
Claim your profile

City Ranking

Industry Ranking

State Ranking

Estimated Revenue & Financials

  • Samumed's estimated annual revenue is currently $29.6M per year.
  • Samumed received $440.0M in venture funding in November 2018.
  • Samumed's estimated revenue per employee is $155,000
  • Samumed's total funding is $438M.

Employee Data

  • Samumed has 191 Employees.
  • Samumed grew their employee count by -90% last year.
  • Samumed currently has 10 job openings.

Executive Contacts

NameTitle
Steve SvitenkoVice President, Commercial Operations
Mark FinemanSVP, Clinical Development
Dexter PasisClinical Research Associate Manager
Jason CallahanClinical Project Manager
Heekyung ChungManager, Biology
Lamia MerabetSenior Manager Quality Assurance
Monica MengSr. Manager, Project Support Office
Jon BrittManager, Biostatistics
Christine BryantAssociate Director, Medical And Regulatory Writing
Jesse ChanSenior Manager, Quality Assurance

Samumed is a leader in medical research and development for tissue-level regeneration. With our platform's origins in small molecule-based Wnt pathway modulation, we develop therapeutics to address a range of degenerative diseases, regenerative medicine and oncology.

keywords:Biotechnology,Customer Support,Education,Healthcare,Human Resources Hr,Pharmaceuticals

191

Number of Employees

$29.6M

Revenue (est)

10

Current Jobs

-90%

Employee Growth %

$438M

Total Funding

$12B

Valuation

N/A

Accelerator

N/A

Type

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
DiaCarta
$6.7M4310%N/A
Mission Bio
$11.5M7445%N/A
Rigel Pharmaceu...
$45M2904%N/A
ProTrials Resea...
$28.2M1823%N/A
Trace Genomics
$6.4M4137%N/A
Advanced Cell D...
$27.6M1788%N/A
CellMax Life
$6.2M4011%N/A
Vaxart
$4.2M33-15%N/A
Full Spectrum A...
$6.5M425%N/A
Calysta
$7.6M49-2%N/A

Samumed News

08/15/2019 - In conversation with Samumed CEO Osman Kibar: Drugging ...

Founded in 2008, Samumed has spent most of its lifetime working under the radar. It came out of the shadows in 2016 with a war chest of $220 ...

05/02/2019 - Samumed Launches Phase 3 Lorecivivint (SM04690) Clinical ...

SAN DIEGO, May 02, 2019 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that it has finalized the design of its phase 3 clinical ...

02/28/2019 - Samumed Announces Positive End-of-Phase 2 Meeting with ...

SAN DIEGO, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that it has successfully completed an End-of-Phase 2 ...

Samumed Funding

DateAmountRoundLead InvestorsReference
2018-08-07$438.0MA-6Article
2018-11-27$440.0MAVickers Venture PartnersArticle